Form 4: NewAmsterdam Pharma Officer Trades Ordinary Shares

Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co. N.V., reported transactions involving the acquisition and disposition of ordinary shares.

Summary

• Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co. N.V. (NAMS), engaged in several transactions on June 22, 2026.
• Kooij acquired 25,000 ordinary shares at $10.90 per share and an additional 15,000 ordinary shares at $11.90 per share.
• Concurrently, Kooij disposed of 39,700 ordinary shares at a weighted average price of $30.20 (ranging from $29.73 to $30.72) and 300 ordinary shares at $30.73.
• Following these transactions, Kooij beneficially owns 24,353 ordinary shares directly.
• Additionally, 22,000 ordinary shares are subject to restricted stock unit awards that are still subject to vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While there are significant share acquisitions and disposals, they were executed under a pre-defined Rule 10b5-1 plan, mitigating concerns about opportunistic trading.

Positives

• Acquisition of 40,000 ordinary shares at prices below the disposal price, indicating potential for profit.
• The company's Chief Accounting Officer is actively participating in share ownership, which can be seen as a positive signal of confidence.

Negatives

• Disposal of a significant number of shares (39,700) at a price considerably higher than the acquisition prices, suggesting a potential profit-taking by management.
• The disposal of shares at prices significantly higher than recent acquisitions could indicate a belief that the current share price is at a peak.

Risks

• The disposal of a large number of shares by a key officer could be interpreted negatively by the market, potentially impacting share price.
• The existence of 22,000 ordinary shares subject to vesting indicates that a portion of the reported ownership is contingent on continued employment and performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
• Reported transactions executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The adoption of a Rule 10b5-1 plan suggests a pre-arranged strategy for trading, often used to avoid concerns about insider trading while allowing executives to diversify or manage their holdings.

Stakeholder Impact

• Shareholders may interpret the disposal of shares by a senior officer as a signal of potential overvaluation or a lack of further upside, potentially leading to short-term selling pressure.
• Employees, particularly those with stock options or RSUs, may be influenced by the trading activity of senior management.

Next Steps

• The reporting person may provide further details on share sales upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Recommendation

The transactions were conducted under a Rule 10b5-1 plan, indicating a pre-determined strategy rather than a reaction to non-public information. The acquisition of shares at lower prices and disposal at higher prices is a normal part of such plans. Without further context on the company's performance or future prospects, a 'hold' recommendation is prudent, acknowledging the insider activity but not overreacting due to the structured nature of the trades.

Keywords

Form 4, NewAmsterdam Pharma, NAMS, Insider Trading, Share Acquisition, Share Disposal, Ordinary Shares, Chief Accounting Officer, Rule 10b5-1